Moneco Advisors LLC Acquires 8,324 Shares of Biogen Inc. $BIIB

Moneco Advisors LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 562.4% during the third quarter, HoldingsChannel.com reports. The firm owned 9,804 shares of the biotechnology company’s stock after acquiring an additional 8,324 shares during the quarter. Moneco Advisors LLC’s holdings in Biogen were worth $2,215,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Biogen in the second quarter valued at approximately $3,453,878,000. Primecap Management Co. CA bought a new stake in shares of Biogen in the second quarter valued at approximately $3,274,304,000. Wellington Management Group LLP grew its position in Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after buying an additional 155,828 shares in the last quarter. Pictet Asset Management Holding SA grew its position in Biogen by 139.4% during the third quarter. Pictet Asset Management Holding SA now owns 2,039,056 shares of the biotechnology company’s stock worth $460,582,000 after buying an additional 1,187,237 shares in the last quarter. Finally, Amundi grew its position in Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock worth $327,727,000 after buying an additional 726,004 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Biogen Stock Performance

Shares of NASDAQ:BIIB opened at $253.40 on Thursday. Biogen Inc. has a 1 year low of $158.05 and a 1 year high of $261.00. The stock has a market capitalization of $37.46 billion, a price-to-earnings ratio of 108.29, a price-to-earnings-growth ratio of 2.87 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. The company’s 50 day simple moving average is $232.21 and its 200 day simple moving average is $204.26.

Biogen (NASDAQ:BIIB – Get Free Report) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company earned $4.81 earnings per share. As a group, research analysts predict that Biogen Inc. will post 12.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of recent research reports. Canaccord Genuity Group raised their price objective on Biogen from $248.00 to $272.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Wells Fargo & Company increased their target price on Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Wall Street Zen upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, October 31st. Piper Sandler restated an “overweight” rating and issued a $305.00 price target (up from $245.00) on shares of Biogen in a research report on Monday. Finally, Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Biogen currently has a consensus rating of “Moderate Buy” and an average price target of $254.41.

Get Our Latest Stock Analysis on Biogen

About Biogen

(Free Report)

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

See Also

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.